[go: up one dir, main page]

PE20091157A1 - Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 - Google Patents

Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155

Info

Publication number
PE20091157A1
PE20091157A1 PE2008002119A PE2008002119A PE20091157A1 PE 20091157 A1 PE20091157 A1 PE 20091157A1 PE 2008002119 A PE2008002119 A PE 2008002119A PE 2008002119 A PE2008002119 A PE 2008002119A PE 20091157 A1 PE20091157 A1 PE 20091157A1
Authority
PE
Peru
Prior art keywords
treatment
androgen receptor
triazolo
conditions associated
compounds
Prior art date
Application number
PE2008002119A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Neil James Hales
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091157A1 publication Critical patent/PE20091157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA (Ic) DONDE X3 ES CH O N; R4 ES C2F2, CF3 O CClF2; Y ES CH, COH O N; R14 ES H O CH3; n Y p SON CADA UNO 1 O 2; L1 ES UN ENLACE DIRECTO, -S-, -S(O)-, -S(O)2-, ENTRE OTROS; J ES ARILO, UN ANILLO CARBOCICLICO DE 3 A 6 MIEMBROS MONOCICLICO, HETEROCICLICO DE 4 A 7 MIEMBROS, ENTRE OTROS; L3 ES -C(O)-(CH2)q, -O-(CH2)q, (CH2)q, ENTRE OTROS, DONDE q ES DE 0 A 3; R12 ES OH, HALO, AMINO, CN, OXO, ENTRE OTROS; r ES DE 0 A 3. SON COMPUESTOS PREFERIDOS: 4-[[4-[3-(TRIFLUOROMETIL)-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZIN-6-IL]PIPERAZIN-1-IL]METIL]BENZONITRILO, 3-(TRIFLUOROMETIL)-6-[4-[[3-(TRIFLUOROMETIL)FENIL]METIL]PIPERAZIN-1-IL]-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZINA, 4-PIRIDIN-3-IL-1-[3-(TRIFLUOROMETIL)-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZIN-6-IL]PIPERIDIN-4-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR DE ANDROGENO (AR) SIENDO UTILES EN EL TRATAMIENTO DEL CANCER DE PROSTATA
PE2008002119A 2007-12-21 2008-12-18 Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 PE20091157A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1575507P 2007-12-21 2007-12-21
US9609008P 2008-09-11 2008-09-11
US10780408P 2008-10-23 2008-10-23

Publications (1)

Publication Number Publication Date
PE20091157A1 true PE20091157A1 (es) 2009-09-03

Family

ID=40428336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002119A PE20091157A1 (es) 2007-12-21 2008-12-18 Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155

Country Status (23)

Country Link
US (1) US8003649B2 (es)
EP (1) EP2235010A1 (es)
JP (1) JP2011507824A (es)
KR (1) KR20100099742A (es)
CN (1) CN101952286A (es)
AR (1) AR069911A1 (es)
AU (1) AU2008339572B2 (es)
BR (1) BRPI0821676A2 (es)
CA (1) CA2709514A1 (es)
CL (1) CL2008003846A1 (es)
CO (1) CO6331441A2 (es)
CR (1) CR11524A (es)
DO (1) DOP2010000195A (es)
EA (1) EA017144B1 (es)
EC (1) ECSP10010291A (es)
IL (1) IL206284A0 (es)
NI (1) NI201000110A (es)
NZ (1) NZ586913A (es)
PE (1) PE20091157A1 (es)
TW (1) TW200927121A (es)
UY (1) UY31559A1 (es)
WO (1) WO2009081197A1 (es)
ZA (1) ZA201004227B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
WO2010092371A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
MX2011012055A (es) * 2009-05-11 2011-12-06 Astrazeneca Ab [1,2,4] triazolo [4,3-b] piridazinas como ligandos del receptor de androgeno.
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
RS54945B1 (sr) 2009-10-23 2016-11-30 Janssen Pharmaceutica Nv Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
WO2011097496A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
US9765075B2 (en) * 2013-05-13 2017-09-19 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
HK1220446A1 (en) * 2013-06-10 2017-05-05 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
NO2719005T3 (es) 2014-07-28 2018-01-20
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3285764B1 (en) * 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
DK3426251T3 (da) 2016-03-10 2022-06-20 Janssen Pharmaceutica Nv Fremgangsmåder til behandling af depression under anvendelse af orexin-2-receptorantagonister
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201806663D0 (en) * 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
CR20210240A (es) 2018-11-14 2021-06-08 Janssen Pharmaceutica Nv Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina
US12521386B2 (en) * 2018-12-11 2026-01-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN114685601B (zh) * 2020-12-30 2024-10-18 财团法人工业技术研究院 雄性激素受体结合分子及其用途
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
WO2025099660A1 (en) * 2023-11-10 2025-05-15 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3390744B2 (ja) 1998-09-22 2003-03-31 山之内製薬株式会社 シアノフェニル誘導体
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
JP4797021B2 (ja) * 2004-10-01 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase

Also Published As

Publication number Publication date
TW200927121A (en) 2009-07-01
ZA201004227B (en) 2011-10-26
ECSP10010291A (es) 2010-07-30
DOP2010000195A (es) 2010-08-31
UY31559A1 (es) 2009-08-03
EA017144B1 (ru) 2012-10-30
WO2009081197A1 (en) 2009-07-02
EA201000946A1 (ru) 2010-12-30
CR11524A (es) 2010-08-05
CN101952286A (zh) 2011-01-19
CA2709514A1 (en) 2009-07-02
CL2008003846A1 (es) 2010-02-05
JP2011507824A (ja) 2011-03-10
AR069911A1 (es) 2010-03-03
CO6331441A2 (es) 2011-10-20
US20100016279A1 (en) 2010-01-21
NI201000110A (es) 2012-05-14
US8003649B2 (en) 2011-08-23
KR20100099742A (ko) 2010-09-13
BRPI0821676A2 (pt) 2015-06-16
NZ586913A (en) 2012-06-29
AU2008339572B2 (en) 2012-05-10
IL206284A0 (en) 2010-12-30
AU2008339572A1 (en) 2009-07-02
EP2235010A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
PE20091157A1 (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
GEP20166472B (en) Androgen receptor modulating compounds
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
AR051326A1 (es) Pirazolobenzodiazepinas disustituidas
RU2019143759A (ru) Новое соединение бифенила или его соль
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20081228A1 (es) Compuesto heteromonociclico
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
NZ600430A (en) Spiro-oxindole mdm2 antagonists
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
AR064010A1 (es) Inhibidores de la actividad de la akt
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20121137A1 (es) Antagonistas del receptor de cgrp
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
NZ579296A (en) Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
AR064547A1 (es) Derivados de azaspiro como antagonistas del receptor v1a
PE20142186A1 (es) Derivados biciclicos de pirazinona

Legal Events

Date Code Title Description
FC Refusal